Further Characterisation Of The Role Of HSSB1 In DNA Repair And Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,526.00
Summary
To date, all breast cancer predisposition genes identified play an important role in the DNA damage repair pathway. We have characterised a new protein designated as hSSB1, which plays a crucial role in the maintenance of genomic stability by protecting us from DNA damage. Significantly, evidence strongly suggests an interaction of hSSB1 with the breast cancer susceptibility protein BRCA2. This project will investigate the role of hSSB1 in breast cancer predisposition and DNA damage repair.
An In-vivo Model Of Acquired Chemoresistance In Small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$363,827.00
Summary
Lung cancer is a common and lethal disease in our community. In this project, we explore how a very aggressive form of lung cancer becomes resistant to chemotherapy. To do this, we use a new mouse model of lung cancer in which we can study how human lung cancer cells develop resistance to chemotherapy in vivo. Understanding these pathways will help us to better treat lung cancer with chemotherapy.
Investigation Of Cancer Predisposition In Heterozygous Carriers Of The ATM
Funder
National Health and Medical Research Council
Funding Amount
$822,750.00
Summary
Individuals with the human genetic disorder ataxia-telangiectasia are prone to cancer development and so also are their parents and relatives (carriers) who have one defective copy of the gene. This is a multisystem disease that is also characterized by neurodegeneration, immunodeficiency, infertility and extreme sensitivity to radiation. This project is designed to generate a mouse model of this disease to investigate cancer susceptibility in carriers of the defective gene. The specific mutatio ....Individuals with the human genetic disorder ataxia-telangiectasia are prone to cancer development and so also are their parents and relatives (carriers) who have one defective copy of the gene. This is a multisystem disease that is also characterized by neurodegeneration, immunodeficiency, infertility and extreme sensitivity to radiation. This project is designed to generate a mouse model of this disease to investigate cancer susceptibility in carriers of the defective gene. The specific mutation to be introduced into the mouse has been described in a patient with breast cancer and it has been shown to interfere with the normal function of the ATM protein. The mouse model is expected to reflect closely the human disease and will provide the opportunity to monitor heterozygous carriers for the development of cancer. This model is expected to confirm the observations in humans and provide a resource to understand susceptibility to develop cancer. The model will also address the issue of exposure to low dose radiation and risk of developing cancer.Read moreRead less
Genetic And Epigenetic Biomarkers In High Risk Colorectal Cancer: Predicting Risk Of Recurrence
Funder
National Health and Medical Research Council
Funding Amount
$64,631.00
Summary
The main aim of this project is to define the prognostic and predictive significance of specific genetic events in patients with high risk (stage III) colorectal cancer. We attempt to explore the differences between primary tumours from patients with and without recurrence at three years. Data from the project will then be used to define a limited set of biomarkers which will aid in clinical decisions regarding the need for adjuvant chemotherapy after surgery for high risk colorectal cancer.
I am a molecular biologist and my research is focussed on the importance of epigenetics in early development and disease, especially in cancer. My research to date has resulted in many ground-breaking discoveries relating to DNA methylation patterns, that
Synthetic Analogues Of The Actinomycin, Quinamycin And Nogalamycin Groups Of Antitumour Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$376,433.00
Summary
The principal difficulty in the treatment of the common solid tumours that cause the majority of cancer deaths is the problem of drug resistance. For example, many patients with cancer of the lung, breast or colon respond well to drug treatment with their tumours initially regressing, only to return later in an aggressive drug-resistant form. In this event, the inevitable outcome is that the tumour grows through drug treatment and the patient eventually succumbs and dies. This is also a familiar ....The principal difficulty in the treatment of the common solid tumours that cause the majority of cancer deaths is the problem of drug resistance. For example, many patients with cancer of the lung, breast or colon respond well to drug treatment with their tumours initially regressing, only to return later in an aggressive drug-resistant form. In this event, the inevitable outcome is that the tumour grows through drug treatment and the patient eventually succumbs and dies. This is also a familiar scenario in the treatment of adults with leakaemias and non-Hodgkins lymphomas. The underlying cause of drug resistance is the genetic instability of cancer cells which results in tumours that are heterogeneous, making it almost inevitable that a cancer cell will arise that is resistant to treatment. There are many mechanisms of resistance, some of which are peculiar to particular drug types, some are permeability barriers and some involve genetic deregulation of the biochemistry of cell death. One way of subverting resistance is by the use of drugs whose mechanism of action is novel so that the tumour is challenged to devise a new defense. Here, we are attempting to develop synthetic analogues of a class of naturally- occurring antitumour antibiotic whose mechanism of action is unusual but which has not been exploited by medicinal chemists because of the difficulty of the chemistry involved. These antibiotics work by binding to DNA and inhibiting the first step in the process whereby genes are turned into proteins. We have designed compounds that are chemically accessible that our preliminary work suggests mimic the DNA-binding and biological properties of the natural antibiotics. The proposed work will enable us to evaluate whether this new class of agent has experimental antitumour activity, particularly amongst drug-resistant tumours.Read moreRead less